For the quarter ending 2025-12-31, IXHL had -$3,700K decrease in cash & cash equivalents over the period. -$4,626K in free cash flow.
| Cash Flow | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|
| Change in fair value of convertible rights | - | - | -299 |
| Change in fair value of warrant liabilities | - | - | 21,925 |
| Loss on extinguishment | - | - | -1,472 |
| Effect of exchange rate changes on cash | -388 | 269 | - |
| Net loss | -6,521 | -6,407 | -46,885 |
| Depreciation and amortization | 59 | 66 | 246 |
| Unrealized loss on foreign currency remeasurement | -24 | -13 | -294 |
| Non-cash expense of eloc commitment | - | - | 1,048 |
| Non-cash interest expense | - | - | 302 |
| Stock-based compensation expense | 2,279 | 2,626 | 2,609 |
| Prepaid expenses and other current assets | -51 | -299 | 189 |
| R&d tax incentive | 558 | 364 | -5,579 |
| Trade and other payables | 44 | -5,396 | 1,385 |
| Net cash used in operating activities | -4,622 | -9,163 | -12,513 |
| Purchase of property, plant and equipment | 4 | 2 | 8 |
| Investment of joint venture | 0 | 40 | - |
| Net cash used in investing activities | -4 | -42 | -8 |
| Proceeds received from facility agreement | - | - | 4,282 |
| Repayment of facility agreement | - | - | 4,459 |
| Proceeds from share issuance | 2,197 | 69,465 | 48,343 |
| Share issuance costs | 91 | 2,288 | 747 |
| Warrant issuance costs | - | - | 125 |
| Proceeds from issuance of convertible debt | - | - | 2,779 |
| Cancellation of warrants | - | - | 24,769 |
| Repayment of convertible debt | - | - | 3,795 |
| Debt issuance costs | - | - | 113 |
| Share repurchase | 1,179 | - | - |
| Net cash provided by financing activities | 927 | 67,177 | 21,396 |
| Net increase/(decrease) in cash, cash equivalents, and restricted cash | -3,700 | 57,972 | 8,875 |
| Cash and cash equivalents at beginning of period | 73,280 | 15,039 | - |
| Cash and cash equivalents at end of period | 69,193 | 73,280 | - |
Incannex Healthcare Inc. (IXHL)
Incannex Healthcare Inc. (IXHL)